Last reviewed · How we verify

NCT05866640

Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Recruiting now EARLY_PHASE1 Last updated 25 February 2025
What this trial tests

EARLY_PHASE1 trial testing F2 filter and delivery system in Aortic Stenosis in 10 participants. Currently enrolling.

Timeline
29 April 2023
Primary endpoint
30 December 2025
30 January 2026

Quick facts

Lead sponsorEnCompass Technologies, Inc.
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment10
Start date29 April 2023
Primary completion30 December 2025
Estimated completion30 January 2026
Sites1 location across Georgia

Drugs / interventions tested

Conditions studied

Sponsor

EnCompass Technologies, Inc.

Who can join

22 and older, any sex, with Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about the safety and performance of the F2 device for cerebral embolic protection in participants with symptomatic aortic stenosis underdoing a Transcatheter Aortic Valve replacement procedure. Participants will complete several neurocognitive assessments and an MRI procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other EnCompass Technologies, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05866640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing